Two cases of opportunistic parasite infections in patients receiving alemtuzumab

Journal of Clinical Pathology

Volumn 65, Issue 1, 2012, Pages 92-95

  Desoubeaux, Guillaume ^a   Caumont, Charline ^a   Passot, Christophe ^a   Dartigeas, Caroline ^a   Bailly, Éric ^a   Chandenier, Jacques ^a   Duong, Thanh Haï ^a  

^a CHU BRETONNEAU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB;

AGED; ARTICLE; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM; DIAGNOSTIC TEST; DIARRHEA; ENTEROCYTOZOON; FEMALE; FUNGUS IDENTIFICATION; HIGH RISK PATIENT; HUMAN; IMMUNE STATUS; INFECTION SENSITIVITY; LYMPHOCYTE COUNT; MALE; MICROSPORIDIOSIS; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM; ENTEROCYTOZOON; FEMALE; HUMANS; IMMUNITY, CELLULAR; MALE; MICROBIOLOGICAL TECHNIQUES; MICROSPORIDIOSIS; OPPORTUNISTIC INFECTIONS;

EID: 84355162883     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2011-200403     Document Type: Article

References (30)

1. Martin SI, Marty FM, Fiumara K, et al. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis 2006;43:16-24. (Pubitemid 43939071)
2. Nosari A, Tedeschi A, Ricci F, et al. Characteristics and stage of the underlying diseases could determine the risk of opportunistic infections in patients receiving alemtuzumab. Haematologica 2008;93:e30-1. (Pubitemid 351397734)
3. Peleg AY, Husain S, Kwak EJ, et al. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis 2007;44:204-12. (Pubitemid 46079982)
4. Didier ES. Microsporidiosis: an emerging and opportunistic infection in humans and animals. Acta Trop 2005;94:61-76. (Pubitemid 40445381)
5. Collinet-Adler S, Ward HD. Cryptosporidiosis: environmental, therapeutic, and preventive challenges. Eur J Clin Microbiol Infect Dis 2010;29:927-35.
6. Kelkar R, Sastry PS, Kulkarni SS, et al. Pulmonary microsporidial infection in a patient with CML undergoing allogeneic marrow transplant. Bone Marrow Transplant 1997;19:179-82. (Pubitemid 27068256)
7. Orenstein JM, Russo P, Didier ES, et al. Fatal pulmonary microsporidiosis due to encephalitozoon cuniculi following allogeneic bone marrow transplantation for acute myelogenous leukemia. Ultrastruct Pathol 2005;29:269-76. (Pubitemid 40993750)
8. Yazar S, Eser B, Yalçin S, et al. A case of pulmonary microsporidiasis in an acute myeloblastic leukemia (AML) - M3 patient. Yonsei Med J 2003;44:146-9. (Pubitemid 36322528)
9. Yoken J, Forbes B, Maguire AM, et al. Microsporidial endophthalmitis in a patient with acute myelogenous leukemia. Retina 2002;22:123-5. (Pubitemid 41070769)
10. Ferrajoli A, O'Brien S, Keating MJ. Alemtuzumab: a novel monoclonal antibody. Expert Opin Biol Ther 2001;1:1059-65.
11. Bologna L, Gotti E, Manganini M, et al. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. J Immunol 2011;186:3762-9.
12. Jaglowski SM, Alinari L, Lapalombella R, et al. The clinical application of monoclonal antibodies in chronic lymphocytic leukemia. Blood 2010;116:3705-14.
13. Poiré X, van Besien K. Alemtuzumab in allogeneic hematopoetic stem cell transplantation. Expert Opin Biol Ther 2011;11:1099-111.
14. Safdar N, Smith J, Knasinski V, et al. Infections after the use of alemtuzumab in solid organ transplant recipients: a comparative study. Diagn Microbiol Infect Dis 2010;66:7-15.
15. Fox EJ. Alemtuzumab in the treatment of relapsing-remitting multiple sclerosis. Expert Rev Neurother 2010;10:1789-97.
16. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002;99:3554-61. (Pubitemid 34534522)
17. Rigal E, Gateault P, Lebranchu Y, et al. [Therapeutic monoclonal antibodies: update on the risk of opportunistic infections] (In French). Med Sci (Paris) 2009;25:1135-40.
18. Thursky KA, Worth LJ, Seymour JF, et al. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*. Br J Haematol 2006;132:3-12. (Pubitemid 43381565)
19. Morrison VA. Infectious complications in patients with chronic lymphocytic leukemia: pathogenesis, spectrum of infection, and approaches to prophylaxis. Clin Lymphoma Myeloma 2009;9:365-70.
20. Nguyen DD, Cao TM, Dugan K, et al. Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Clin Lymphoma 2002;3:105-10. (Pubitemid 35277016)
21. Bassetti M, Repetto E, Mikulska M, et al. Cryptococcus neoformans fatal sepsis in a chronic lymphocytic leukemia patient treated with alemtuzumab: case report and review of the literature. J Chemother 2009;21:211-14.
22. Pitini V, Cascio A, Arrigo C, et al. Visceral leishmaniasis after alemtuzumab in a patient with chronic lymphocytic leukaemia. Br J Haematol. Published Online First: 25 July 2011. doi:10.1111/j.1365-2141.2011.08802.x. http://www.ncbi.nlm.nih.gov/pubmed/21790529 (accessed 12 Aug 2011).
23. Salvana EM, Salata RA. Infectious complications associated with monoclonal antibodies and related small molecules. Clin Microbiol Rev 2009;22:274-90.
24. Lundin J, Porwit-MacDonald A, Rossmann ED, et al. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia 2004;18:484-90. (Pubitemid 38425862)
25. O'Brien SM, Kantarjian HM, Thomas DA, et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 2003;98:2657-63. (Pubitemid 37509530)
26. Oscier D, Fegan C, Hillmen P, et al.; Guidelines Working Group of the UK CLL Forum. British Committee for Standards in Haematology. Guidelines on the diagnosis and management of chronic lymphocytic leukaemia. Br J Haematol 2004;125:294-317.
27. Jamet D, Quinio D, Moalic E, et al. [Systemic microsporidiosis and toxoplasmosis in a patient with T prolymphocytic leukemia] (In French). Med Mal Infect 2009;39:406-8.
28. Chioralia G, Trammer T, Kampen H, et al. Relevant criteria for detecting microsporidia in stool specimens. J Clin Microbiol 1998;36:2279-83. (Pubitemid 28324080)
29. Rossignol JF, Ayoub A, Ayers MS. Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomized, double-blind, placebo-controlled study of nitazoxanide. J Infect Dis 2001;184:103-6. (Pubitemid 32568508)
30. Molina JM, Tourneur M, Sarfati C, et al. Fumagillin treatment of intestinal microsporidiosis. N Engl J Med 2002;346:1963-9. (Pubitemid 34651356)